Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

According to the company, medical essentials and interventional lead the medical technology unit's business lines, bringing ...

(This Feb. 5 story has been refiled to correct the name of the unit to biosciences and diagnostic solutions, from life sciences, in the headline and paragraphs 1 and 4) (Reuters) - Becton Dickinson ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

We believe Biosciences and Diagnostic Solutions is expected to deliver substantial value as a pure-play leader in life sciences and will be well-positioned to execute on its unique and compelling ...

As per Future Market Insights, PSG devices are expected to be the most preferred sleep apnea diagnostic systems during the ...

Becton Dickinson BDX1.16%increase; green up pointing triangle and Co. said it plans to break off its bioscience and diagnostic solutions business to focus on medical technology. Chief Executive ...

BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...